• Link to X
  • Link to Facebook
  • Link to Instagram
  • Link to LinkedIn
  • Link to Youtube
  • Donate to fight Lafora disease!
  • Contact Us
info@chelseashope.org
Chelsea's Hope Lafora Children Research Fund
  • What is Lafora Disease?
    • About Lafora Disease
    • ICD-10 Codes for Lafora Disease
    • Lafora Disease Symptom Checker
    • Lafora Disease Therapy
    • Lafora Disease Clinical Pipeline Progress
    • ION283 Safety Study
    • Family Stories
  • About Us
    • Chelsea’s Story
    • Leadership Team
    • Advisory Board
    • Contact
  • News
  • Resources
    • For Families & Caregivers
      • Newly Diagnosed
      • Tips for Lafora Disease Families
      • Bereavement Support
      • G-Tube Tips – A Mother’s Perspective
      • Lafora Clinical Network Registry
      • Refer Your Clinician to the Registry
    • For Researchers
      • Lafora Mutations Database
      • Lafora Canine Registry and Database
      • Apply to Join the Clinical Registry
  • Events
    • 2026 Lafora Science Symposium
    • Courage in Care: Lafora Caregiver Series
    • Lafora Disease Roundtables
  • Get Involved
    • Ways to Give
    • Volunteer
    • Join Canine Registry
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Tag Archive for: safety study

ION238 Safety Study Update February 2025

Safety Study Update – February 2025

February 20, 2025/by Christine Kelly

We are excited to share an update about the ION283 Safety Study: the team at UTSW can continue enrolling patients. 

In December 2024, the first patient in the Lafora Disease Safety Study at the University of Texas Southwestern Medical Center (USTW) received their first dose of ION283, a treatment designed to halt disease progression. Last month, that patient completed their one-month check-up with no safety issues detected. This allowed a second patient to receive their first dose of ION283 in January. Earlier in February, the second patient completed their one-month safety check. The safety board at the university reviewed the safety data, giving an all clear to proceed as planned with the study.

The first ten families who applied to participate in the study will receive notification from the team at UTSW when there is enough money available to enroll them in the study. We are pleased to share that the third patient is en route to Dallas, and the fourth has been notified.

As a community, we must continue raising funds so all 10 patients can receive treatment. The data collected from this study will help accelerate the approval process so that we can expand access for other patients to receive this drug. However, we need to complete the enrollment for this study first and get the data we need. So far, we have raised more than $977,000 as a community. We must reach 1.5 million dollars by May 2025 to fully fund the study. 

We will continue to keep the Lafora community informed about the progression of the Safety Study. Any questions not answered in our FAQs about the study can be directed to Chelsea’s Hope at info@chelseashope.org.

Read Press Release
https://chelseashope.org/wp-content/uploads/2025/02/Feb.-2025-safety-study-update.png 628 1200 Christine Kelly https://chelseashope.org/wp-content/uploads/2022/02/ChelseasHope1.png Christine Kelly2025-02-20 11:54:572025-02-22 12:59:57Safety Study Update – February 2025
Text says 'ION283 Safety Study ASO Therapy for Lafora Disease' over a background image of the Dallas, Texas, skyline

Now Recruiting: ION283 Safety Study

November 17, 2024/by Christine Kelly

The application packet for the ION283 safety study is now available!

You can view the application as a PDF or download a Word document.

Please read the email below from Dr. Minassian:


“Dear Lafora disease patients and families,

We are now ready to receive referrals for consideration for inclusion into the clinical trial: Safety and Efficacy of Intrathecally Administered ION283 in Patients with
Lafora Disease

This email relates to the prescreening phase.  Below are the requirements for the prescreening.  If a patient passes the prescreening, they will be placed on a list of prospective patients to participate in the trial.  Each patient invited to participate will still need to meet broader inclusion-exclusion criteria at the time of screening in Dallas.  These final inclusion-exclusion criteria are listed in the above website.

Only referrals from neurologists will be accepted, except where it is impossible for the patient to have a neurologist (we are thinking of the patient in Gaza), in which case another doctor or local medic can make the referral.

Attached is a document that contains a prescreening table and the Lafora Disease Performance Scale, both of which should be completed by the referring neurologist.  All parts of the document must be completed.  All documents and video mentioned in the prescreening table must be provided at the time of referral precisely as described.

Referrals must be sent by the neurologist from his or her email address to LDrecruiting@utsouthwestern.edu as a single email containing all the attachments.  Please note that our email system cannot accept files that are larger than 50 Mb total.  Therefore, make the video short and of low quality.  Just enough to show the patient walking ten steps independently.

The list of prospective participants will be generated on a first-come first-served basis, where first-come means that all the above requirements are included in the referral.  Any referral that has any component missing will not be accepted and will be returned.

The study will only include 10 participants.  Therefore, the first 10 on the first-come list will be invited to Dallas for formal screening toward potentially entering the study.  If any patient among the first 10 fails to meet inclusion-exclusion criteria at the time of final screening in Dallas, then this will open a slot for a subsequent patient on the list.

The upper age limit is 18.  We understand this to mean any patient before their 19th birthday at the time of final screening in Dallas.  In case among the first 10 patients passing prescreening there is a patient whose turn in the list means they will age out of their 19th birthday at the time of the final screen in Dallas, such a patient may be moved up the list as long as this does not affect the age-criterion admissibility of the remaining patients.

Thank you for considering participation in this clinical trial.

Berge A. Minassian, MD
Principal Investigator
University of Texas Southwestern”

Our deepest gratitude goes to Dr. Minassian, Dr. Joshi, Dr. Verma, Dr. Messahel, and the entire team at UTSW for making this possible. We are also thankful for Ionis’ drug donation and our community’s collective fundraising efforts. We can’t stop now!

Please help us share this information, and good luck to everyone applying.

View PDF Application Download Application as a Word Document
https://chelseashope.org/wp-content/uploads/2024/04/ION283-Safety-Study.png 628 1200 Christine Kelly https://chelseashope.org/wp-content/uploads/2022/02/ChelseasHope1.png Christine Kelly2024-11-17 07:32:542024-11-17 07:34:16Now Recruiting: ION283 Safety Study
BECAUSE WE HAVE HOPE Lafora Holiday Season Auction 2024

Announcing Holiday Season Auction

October 29, 2024/by Christine Kelly

This November, we are hosting a holiday season auction to raise money for the upcoming ION283 safety study.

Bidding will open on November 1st and continue through the 30th. 100% of the profits will go toward the safety study.

Each piece has been donated by the Lafora families or affiliates. Check out our page to see what items are already available for bidding. We invite you to bid on an item to purchase or share this auction with your family and friends via this link: https://givebutter.com/c/laforaauction/auction.

How it will work

Some items will have a unique bidding timeline, but the entire online auction will run throughout November. Generous supporters have donated the items from around the world!

You will have to register to bid here: https://givebutter.com/c/laforaauction/auction.

Please review the details and shipping for each item you bid on. Some items have additional shipping costs, while others only ship to certain countries.

Can you help us?

This is an open call for in-kind donations for our holiday season auction! We request artwork, books, clothing, jewelry, tickets, vacations, and passes to events in your country.

Please email us with the subject “November Auction Donation” to get involved. You can donate items until November 24th.

Items available

Custom made Cruella costume
Tuscan Treasures Vacation
Passport to Paradise Vacation
Mexican Moments Vacation
Handmade gifts from Cel-Luz
Pride and Prejudice
Broad Museum Tickets
Painting by Niki
Painting by Angelina
https://chelseashope.org/wp-content/uploads/2024/10/Holiday-Season-Auction-News-Post-Featured-Image.png 628 1200 Christine Kelly https://chelseashope.org/wp-content/uploads/2022/02/ChelseasHope1.png Christine Kelly2024-10-29 09:33:522024-11-01 13:19:32Announcing Holiday Season Auction
ION283 Safety Study Approval ASO Therapy for Lafora Disease

ION283 Safety Study Approved

August 14, 2024/by Christine Kelly

We just learned from Dr. Minassian that the FDA has approved the ION283 Safety Study!

We are so grateful for your continuous support, for Dr. Minassian and his team at UTSW, Dr. Messahel, IONIS, and everyone involved for getting us here.

Our patient community has been a driving force in supporting reaching this stage and we can celebrate another step forward today. We hope this will lead to treatments for our children.

Berge A. Minassian, M.D

“30 years in the making, we now have FDA approval to start our ION283 clinical trial.

I would like to thank each of your associations for your support over the years…” – Dr. Berge Minassian

We do not yet have the application site on clinicaltrials.gov or the criteria for inclusion in the Safety Study. Those will be coming in a few weeks. In the meantime, we can continue fundraising and ensuring all patient families learn of this opportunity.

Budget

The estimated cost of the Safety Study is $1.5 million USD. Please remember, donations do not guarantee a spot for your loved one in the trial. We encourage donations through a patient organization. Chelsea’s Hope has an online fundraiser where you can donate and we will transfer the money to UTSW.

France Lafora is also fundraising HERE.

Donate today!


Please help us share this information! 

If you did not get an email update from us earlier, please ensure you are signed up for our mailing list. Once we learn the criteria from Dr. Minassian, we will send out the information to everyone who has signed up for “research updates.” You can contact christine@chelseashope.org to confirm your email preferences with the subject “Check my Chelsea’s Hope Email Preferences.”

Questions? Please check out our FAQs section on our webpage. 

We answer commonly asked questions about the safety study, including what it is, how much it costs, who can participate, and more! If you don’t see an answer to your question, please email katherine@chelseashope.org with the subject “Safety Study Question.”

https://chelseashope.org/wp-content/uploads/2024/08/ION283-Safety-Study-Approval-Featured-Image.png 628 1200 Christine Kelly https://chelseashope.org/wp-content/uploads/2022/02/ChelseasHope1.png Christine Kelly2024-08-14 08:54:522024-08-14 08:54:52ION283 Safety Study Approved
Page 2 of 212

About Chelsea’s Hope

Chelsea’s Hope began as a website in the fall of 2007 to share Chelsea Gerber’s story with family and friends. A 501(c)(3) organization since 2009, we have made an impact by raising awareness, connecting families worldwide, funding research, and maintaining hope.

Our mission is to improve the lives of those affected by Lafora disease and help accelerate the development of treatments. [Read More]

View Chelsea’s Hope Newsletter Archive 

Donate to Lafora Research

Latest News

  • Join in Lafora Body Disease Day 2026!

  • Lafora Therapy Q&A Resources

  • Student Ambassador Applications Open

  • Social Security Added Lafora to Compassionate Allowances List

  • Elpida Therapeutics’ Press Release

  • ION283 to be Developed by Elpida Therapeutics

  • Update on the ION283 Program from Telethon

  • Introducing the Lafora Clinical Network Registry

  • Meet our 2026 Summer Interns!

  • Updates for the Lafora Therapy Pipeline: Requesting information from our Research Community

The mission of Chelsea’s Hope is to improve the lives of those affected by Lafora disease and help accelerate the development of treatments.

Chelsea’s Hope Lafora Children Research Fund is an IRS 501(c)3 nonprofit organization. EIN: 27-1008382

Location imageChelsea’s Hope c/o Dr. Donohue

976 Maywick Dr.

Lexington, KY 40504

info@chelseashope.org

Use ICD-10 code G40.C for Lafora.

    • Follow us on
    • Facebook
    • Instagram
    • Twitter
    • LinkedIn
    • YouTube
    • TikTok
ION283 Safety Study
Copyright © 2017-2026 Chelsea's Hope Lafora Children Research Fund. All Rights Reserved.
  • Home
  • News
  • About Lafora Disease
  • Donate
  • Contact
  • Privacy Policy – Other Policies
Scroll to top Scroll to top Scroll to top